Therasense, Inc. v. Becton, Dickinson and Company

745 F.3d 513, 109 U.S.P.Q. 2d (BNA) 2147, 2014 WL 943184, 2014 U.S. App. LEXIS 4582
CourtCourt of Appeals for the Federal Circuit
DecidedMarch 12, 2014
Docket2012-1504
StatusPublished
Cited by18 cases

This text of 745 F.3d 513 (Therasense, Inc. v. Becton, Dickinson and Company) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Therasense, Inc. v. Becton, Dickinson and Company, 745 F.3d 513, 109 U.S.P.Q. 2d (BNA) 2147, 2014 WL 943184, 2014 U.S. App. LEXIS 4582 (Fed. Cir. 2014).

Opinions

Opinion for the court filed by Chief Judge RADER. Dissenting-in-part opinion filed by Circuit Judge DYK.

RADER, Chief Judge.

Becton, Dickinson and ■ Company (Bec-ton) and Nova Biomedical Corporation (Nova) appeal the denial of various fees sought based on an eight-year long patent infringement suit in the United States District Court for the Northern District of California involving patents owned by Therasense, Inc. (now known as Abbott [515]*515Diabetes Care, Inc.) and Abbott Laboratories (collectively, Abbott). Because this court agrees with the district court that Becton and Nova are not entitled to fees on fees, pre-judgment interest, and post-judgment fees calculated specifically from the date the district court deemed the case exceptional, this court affirms.

I.

In March 2004, Becton sued Abbott in the United States District Court for the District of Massachusetts seeking a declaratory judgment of noninfringement of U.S. Patent Nos. 6,143,164 (’164 patent) and 6,592,745 (’745 patent). The product at issue was Becton’s blood glucose test strip, called the BD Test Strip. In response, Abbott sued Becton for patent infringement in the Northern District of California alleging that Becton’s BD Test Strip infringed the '164 patent, the '745 patent, as well as U.S. Patent No. 5,820,551 (’551 patent). The district court in Massachusetts transferred its case to the Northern District of California. Abbott then sued Nova, Becton’s supplier, alleging infringement of the same patents. In August 2005, Abbott sued Bayer Healthcare LLC (Bayer), alleging that Bayer’s Microfill and Autodisc blood glucose strips infringed the '551 and '745 patents. The Northern District of California consolidated all of the cases.

The district court granted summary judgment of noninfringement for all defendants with respect to all asserted claims of the '164 and '745 patents. Therasense, Inc. v. Becton, Dickinson & Co., 560 F.Supp.2d 835, 854, 880 (N.D.Cal.2008). The district court also found nearly all of the asserted claims of the '745 patent to be invalid due to anticipation. Id. Following a bench trial, the district court determined that claims 1-4 of the '551 patent were invalid due to obviousness. Therasense, Inc. v. Becton, Dickinson & Co., 565 F.Supp.2d 1088, 1127 (N.D.Cal.2008), vacated in part, 649 F.3d 1276, 1296 (Fed.Cir.2011) (en banc). The district court also held the '551 patent unenforceable for inequitable conduct. Id. On August 21, 2008, the district court found the case concerning the '551 patent to be exceptional and awarded Becton and Nova costs and fees under 35 U.S.C. § 285. On March 19, 2009, the district court determined that Abbott owed Becton and Nova $5,949,050 in attorney’s fees with payment specifically due “following the exhaustion of all appeals ... regarding the validity and unen-forceability of the '551 patent, if the Court’s inequitable conduct judgment is upheld on appeal.” J.A. 14578.

Abbott appealed the district court’s judgments of invalidity, unenforceability, and noninfringement. Abbott did not appeal the August 21, 2008 exceptional case finding or the March 19, 2009 fee award. On appeal, a panel of this court unanimously upheld the judgments of nonin-fringement and invalidity. Therasense, Inc. v. Becton, Dickinson & Co., 593 F.3d 1289, 1311 (Fed.Cir.2010), vacated, 374 Fed.Appx. 35 (Fed.Cir.2010). On the issue of unenforceability, a divided panel affirmed. Id. at 1312-25 (Linn, J., dissenting). Abbott then petitioned for rehearing en banc, which was granted. Therasense, 374 Fed.Appx. at 35.

Sitting en banc, this court reinstated, and affirmed, the panel decision regarding the district court’s judgment of obviousness, noninfringement, and anticipation. Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276, 1297 (Fed.Cir.2011) (en banc). However, after altering the standard for inequitable conduct, the en banc court vacated the district court’s inequitable conduct judgment and remanded for further proceedings. Id. at 1285.

[516]*516Applying the new standard on remand, the district court concluded anew that the '551 patent was procured through inequitable conduct. Therasense v. Becton, Dickinson and Co., 864 F.Supp.2d 856, 858 (N.D.Cal.2012). Becton and Nova then moved to supplement the original fee award with (1) appellate and remand fees and expenses; (2) fees spent seeking additional fees; (3) pre-judgment interest on fees; and (4) post-judgment interest calculated from the 2.18% rate effective August 21, 2008, i.e., the date the district court found this case to be exceptional. On May 22, 2012, the district court reinstated its March 19, 2009 fee award and added post-judgment interest calculated from May 22, 2012. The district court denied Becton and Nova’s motion for additional fees and interest in all other respects. J.A. 1.4-1.5. On December 3, 2012, Abbott paid Becton and Nova the balance specified in the reinstated March 19, 2009 fee award plus $6,389.12 in post-judgment interest.

Becton and Nova appealed the district court’s denial of additional fees. This court has jurisdiction pursuant to 28 U.S.C. § 1295(a)(1).

II.

Attorney’s fees are authorized by statute upon a district court’s finding that a case is exceptional. 35 U.S.C. § 285. A finding that a case is “exceptional” involves underlying factual determinations which are reviewed for clear error. Wedgetail Ltd. v. Huddleston Deluxe, Inc., 576 F.3d 1302, 1304 (Fed.Cir.2009). This court reviews a district court’s award or denial of such fees for an abuse of discretion. Id. Willfulness and litigation misconduct are among the reasons that a court may find a case to be exceptional. Kilopass Tech., Inc. v. Sidense Corp., 738 F.3d 1302, 1311 (Fed.Cir.2013); MarcTec, LLC v. Johnson & Johnson, 664 F.3d 907, 916 (Fed.Cir.2012). This court reviews a district court’s denial of fees on fees for an abuse of discretion. Mathis v. Spears, 857 F.2d 749, 761 (Fed.Cir.1988). This court reviews de novo a determination of post-judgment interest. Taltech Ltd. v. Esquel Enters. Ltd., 604 F.3d 1324, 1335 (Fed.Cir.2010).

III.

Becton and Nova first contend that they are entitled to itemized appellate and remand fees because the district court’s August 21, 2008 exceptional case finding “permeated” the appeal and remand phases. They argue that these additional fees and costs should receive treatment independent of those awarded at the trial phase.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
745 F.3d 513, 109 U.S.P.Q. 2d (BNA) 2147, 2014 WL 943184, 2014 U.S. App. LEXIS 4582, Counsel Stack Legal Research, https://law.counselstack.com/opinion/therasense-inc-v-becton-dickinson-and-company-cafc-2014.